In the US, New Jersey is a life science powerhouse. It’s home to some of the most influential pharma manufacturers in the world. And today, I want to share with you some of the latest developments coming from this hub.
First off, keep your eye on Dr Reddy’s. Most recently, the company extended its strategic partnership with Gland Pharma to launch Ertapenem, which is the generic version of INVANZ.
Before that, in April, Dr Reddy’s also launched a generic for Albendazole tablets, used for the treatment of a variety of parasitic worm infestations. Considering the demand that the Albenza brand and generics received from the US, I expect this to be popular.
Moving on, Wockhard are on the rise – boosted by the growing US markets for scarlet fever and dexamethasone, whilst also producing COVID-19 vaccines in the fight against the global pandemic.
The same goes for Teva Pharmaceuticals – the world’s largest generics maker – which is set for growth following the launch of two new drugs: Huntington’s disease treatment, Austedo; and migraine product, Ajovy.
Finally, there’s Catalent. A company that’s always up to something big and exciting. Recently, Catalent entered a global innovation partnership with HBC to develop a delayed-release formulation of HBC’s OmeGo fish oil.
Go to my profile page for more about myself and my content.
Are you attracting the very best industry talent to your start-up? For expert advice on how to thrive in today’s life science talent market, watch CM Life Science's latest 30-minute webinar. Click to watch.
Developing and manufacturing drugs is more expensive and complicated than ever before. Many outsource to CDMO's, but which approach truly offers the most value? Click to read more.
As small-molecule CDMOs pivot their businesses to meet the demands of the life science sector, I spoke with CEO & Founder Tia Lyles-Williams to find out what this really means for the industry. Click to find out more.